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Background: Carotid plaque characteristics considerably influence future risk of stroke. 2 
However, the severity of stenosis does not accurately reflect plaque burden in patients 3 
with expansive arterial remodeling. 4 
Objective: The present study aimed to determine the therapeutic outcome of 5 
symptomatic carotid low-grade stenosis with vulnerable plaque based on MRI 6 
characterization. 7 
Methods: We studied 25 (male, n = 23; age, 74.2 ± 5.6 years) of 29 consecutive patients 8 
with symptomatic carotid low-grade stenosis (< 50%) and both high-signal plaque and 9 
expansive remodeling on T1-weighted MR images. The remaining four were excluded 10 
due to impending stroke. A single antithrombotic and statin were administered and 11 
recurrent ischemic stroke was treated with dual antithrombotics. We considered carotid 12 
endarterectomy (CEA) when recurrence was refractory to aggressive medical treatment. 13 
Results: During a 31.3 ± 16.4 month follow-up, 11 of the 25 patients developed a total 14 
of 30 recurrent ischemic events (46.0% per patient-year). The patients’ characteristics 15 
did not significantly differ between the groups with and without recurrence (n = 11 and 16 
n = 14, respectively). Seven of 11 patients in the recurrence group who were treated 17 
with CEA remained free of ischemic events during a postoperative follow-up of 19.1 ± 18 
14.6 months. 19 
Conclusion: Symptomatic low-grade carotid stenosis with vulnerable plaque confirmed 20 
by MRI was associated with a high rate of stroke recurrence that was refractory to 21 
aggressive medical treatment. However, CEA was safe and effective for such patients. 22 
Plaque characterization by MRI has potential for more accurate stroke risk stratification 23 
in the management of carotid low-grade stenosis. 24 
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  Several large multicenter trials have established that carotid endarterectomy (CEA) 2 
significantly reduces stroke risk compared with medical treatment in patients with 3 
moderate to high-grade stenosis, but has no apparent benefit for those with low-grade 4 
stenosis.
1-4
 The assessment of stroke risk from carotid atherosclerosis and determination 5 
of the need for surgical intervention in these randomized trials have been based on 6 
angiographic or ultrasonographic evaluations of stenosis rates.
5
 7 
  Accumulating evidence from recent vascular biology studies indicates that plaque 8 
stability depending on several factors such as plaque components, volume and 9 
morphological characteristics has a large impact on the risk of ischemic events from 10 
atherosclerotic disease.
6-9
 Therefore, the importance of evaluating not only the severity 11 
of stenosis but also the vessel wall itself has been widely recognized for the 12 
management of carotid stenosis. While carotid plaque is generally assessed by 13 
ultrasonography, MRI has been gaining importance in the evaluation of carotid 14 
atherosclerosis with recent technological developments in MRI equipment and imaging 15 
sequencing. Many investigations have demonstrated that carotid MRI can accurately, 16 
non-invasively and objectively provide a considerable amount of information about 17 
carotid atherosclerosis.
10-13
 Moreover, several reports have revealed an important 18 
characteristic of plaque associated with a high risk of stroke on MR images.
14-17
 19 
  Luminography does not necessarily reflect a significant burden of atherosclerotic 20 
plaque due to expansive arterial remodeling in some patients with carotid stenosis.
18,19
 21 
Some might be at high risk for stroke even if angiography reveals only mild stenosis. 22 
Therefore, meticulous risk assessment for ischemic events based on plaque evaluation 23 
in addition to stenosis rates is significant, particularly for patients with low-grade 24 
4 
 




  The present study retrospectively assesses the therapeutic outcomes of symptomatic 3 




  We initially identified 29 consecutive patients with symptomatic carotid low-grade 8 
stenosis (< 50%) accompanied by both high-signal plaque and expansive remodeling on 9 
T1-weighted MR images and a history of presenting at our institution between January 10 
2004 and May 2009. We excluded four with impending stroke and finally studied data 11 
from 25 patients (male, n = 23; age, 74.2 ± 5.6 years). 12 




  Symptomatic patients were defined as those who presented with transient ischemic 15 
attack (TIA), ischemic stroke, or amaurosis fugax in the territory of the ipsilateral 16 
carotid artery at the time of admission. If necessary, patients underwent Holter 17 
monitoring, transesophageal echocardiography or aortic MRI and were checked by 18 
cardiologists. We excluded patients when cardiogenic or aortogenic embolism remained 19 
as the possible etiology. 20 
  Our institutional Ethics Committee approved the study, and all patients provided 21 
written informed consent to analyze their records and publish the findings. 22 
Imaging 23 
  The severity of carotid artery stenosis was evaluated by digital subtraction 24 
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angiography (DSA), computed tomography angiography (CTA), or magnetic resonance 1 
angiography (MRA) using the North American Symptomatic Carotid Endarterectomy 2 
Trial (NASCET) criteria.3 All patients who were scheduled for CEA were also examined 3 
by DSA. 4 
  Atherosclerotic plaque associated with intraplaque hemorrhage (IPH) was diagnosed 5 
when axial T1-weighted 3D gradient-echo black blood (BB)-MRI images revealed high 6 
signals relative to the sternocleidomastoid muscle.
22
 Using axial MR images of areas 7 
with the highest rate of stenosis, relative overall plaque MR signal intensity (roSI) was 8 
measured and compared with plaque MRI signals as described.
23
 9 
  Plaque in the patients who underwent CEA was characterized in more detail by 10 
obtaining several additional MR images as follows. Plaque components were precisely 11 
evaluated using 2D spin-echo BB-MRI,
23
 plaque distribution was evaluated using 12 
long-axis 3D inversion-recovery turbo field echo BB-MRI,
24
 and fibrous cap rupture or 13 
erosion was detected using 3D time of flight (TOF) MRI.
25
 14 
The parameters of each MR imaging sequences were as follows. 15 
Axial black-blood T1-weighted images (3D gradient-echo): field of view, 220 mm; 16 
matrix size, 179 × 256; TR/TE, 30/5.8 msec; flip angle, 20°. 17 
Axial black-blood T1-weighted images (2D double IR-TSE): field of view, 150 mm; 18 
matrix size, 256 × 256; TR/TE, 700-1000 (1 cardiac cycle)/12 msec; flip angle, 110°; 19 
slice thickness, 3.0 mm. 20 
Long-axis T1-weighted images (3D IR turbo field echo): field of view, 150 mm; matrix 21 





Medical treatment was started essentially with a single antithrombotic drug selected 1 
from among aspirin, ticlopidine, clopidogrel and cilostazol. Concomitant hypertension, 2 
hyperlipidemia or diabetes was also treated if necessary. Angiotensin II receptor 3 
blockers and statins were preferentially administered to control hypertension and 4 
hyperlipidemia, respectively. Dual antithrombotic therapy was administered if patients 5 
developed recurrent ischemic stroke or had other ischemic vascular diseases. Ischemic 6 
symptom recurrence was defined as TIA, MRI-confirmed infarct or amaurosis fugax in 7 
the territory of the ipsilateral carotid artery. 8 
  We examined the implementation of CEA when patients presented with more than 9 
two recurrences despite maximal medical therapy, had no other general problems and 10 
consented to surgical intervention. Carotid endarterectomy proceeded under general 11 
anesthesia and with intra-operative monitoring of somatosensory evoked potentials 12 
(SEP) and near-infrared spectroscopy (NIRS). An internal shunt was selectively applied 13 
when the SEP amplitude fell by > 50% or the value of NIRS dropped by > 20%. 14 
Patients continued medical treatment with a single antithrombotic after undergoing 15 
CEA. 16 
Statistical analysis 17 
  We investigated the number of recurrences during follow-up under medical treatment 18 
(period between starting medical treatment and surgical intervention for patients who 19 
underwent CEA). Differences in risk factors, medical regimen, roSI on BB-MRI, and 20 
duration of follow-up were analyzed between groups with and without recurrence. We 21 
also analyzed excised specimens, perioperative complications and postoperative 22 
recurrence after CEA. 23 
  Numerical data are expressed as means ± standard deviation. Statistical significance 24 
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was calculated using Student’s t test or Fisher’s exact test and probability values of < 1 
0.05 were considered significant. All data were statistically analyzed using SPSS 12.0 2 
for Windows. 3 
 4 
Results 5 
  During a follow-up period of 31.3 ± 16.4 months while under medical management, 6 
11 (44%) of 25 patients developed a total of 30 ischemic recurrences (mean, 2.73 ± 1.85 7 
each). The annual recurrence rate under medical management was thus 46.0% per 8 
patient-year. None of age, gender, hypertension, hyperlipidemia, diabetes, ischemic 9 
heart disease, atrial fibrillation, medical regimen, roSI and duration of follow-up 10 
significantly differed between the groups with (n = 11) and without (n = 14) recurrence 11 
(Table 1). 12 
  Seven of 11 patients with recurrence underwent CEA 12.1 ± 10.4 days after the last 13 
ischemic attack. The duration between the initial event and CEA was 35.4 ± 16.9 14 
months and the number of recurrences before CEA was 3.29 ± 2.06. The findings of 15 
DSA revealed a stenosis rate of 27.1 ± 9.9% and obvious ulceration in two patients. 16 
Distinctly high signals of plaque were found on BB-MRI of all patients and the roSI 17 
was 1.84 ± 0.21. Preoperative TOF-MRI assessment of fibrous cap predicted ruptured or 18 
thin fibrous cap in four patients and the quality of MR images from one patient was too 19 
low to evaluate. Internal shunts were used in two of the CEA procedures. Histological 20 
assessment of excised plaques confirmed massive and fresh IPH in all specimens. Five 21 
and two plaques had ruptured and eroded fibrous caps, respectively. Postoperative 22 
diffusion weighted images confirmed the absence of perioperative complications such 23 
as new infarcts in all patients, whereas a neck hematoma and transient hoarseness 24 
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occurred in one patient each. 1 
No ischemic events, including those in the contralateral hemisphere, were confirmed 2 
during the postoperative follow-up period of 19.1 ± 14.6 months (Table 2). 3 
 4 
Illustrative case (Patient No. 5) 5 
  This 73-year-old man with a history of minor stroke presented with right arm 6 
weakness at another hospital during July 2006. He remained under treatment with an 7 
antithrombotic until October 2007 when he was admitted to our hospital with TIA 8 
manifesting as right arm weakness and sensory disturbance. While left carotid 9 
angiography revealed only 26% stenosis with slight luminal irregularity (Fig. 1A), axial 10 
and long-axis BB-MRI clearly showed appreciable high-signal plaque in the form of 11 
expansive remodeling at the carotid bifurcation indicating fresh IPH (Fig. 1B and C). 12 
Neither atherosclerotic plaque along the ascending aorta on aortic MRI nor intracardiac 13 
thrombus on transesophageal echocardiography was detected. Hyperlipidemia was 14 
confirmed by laboratory data upon admission. 15 
  These findings indicated a diagnosis of recurrent ischemic events due to 16 
artery-to-artery embolism originating from the carotid low-grade stenosis with unstable 17 
plaque. The patient was administered with dual antithrombotics and statin. He was 18 
readmitted to our hospital during July 2008 with right arm and leg weakness. Diffusion 19 
weighted images demonstrated fresh multiple minor infarcts in the left hemisphere, 20 
whereas left carotid angiography identified no appreciable elevation in the rate of 21 
stenosis. 22 
  Because not even maximal medical therapy could prevent recurrent ischemic events, 23 
the patient provided written informed consent to undergo CEA on the seventh day from 24 
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the last event. The postoperative course was uneventful and no new infarct was 1 
demonstrated on diffusion weighted images obtained two days postoperatively. 2 
Macroscopic observation of an excised specimen identified a disrupted fibrous cap (Fig. 3 
1D) and histological assessment also revealed a ruptured fibrous cap and massive IPH. 4 
The patient was treated only with aspirin after CEA and he has remained stroke-free at 5 
14 months of follow-up. 6 
 7 
Discussion 8 
  Carotid atherosclerosis has been widely evaluated by ultrasonography, as it is 9 
noninvasive and can provide information about luminal stenosis and, to some extent, 10 
plaque characteristics.
26, 27
 However, limitations are associated with assessing the 11 
carotid artery using this modality since discriminating IPH from a lipid core in 12 
atherosclerotic plaque is less robust. Furthermore, plaque with dense calcification, 13 
stenosis at higher locations and patients with a short neck cannot be fully imaged using 14 
US and interpretation of the results is extremely operator-dependent.
28-30
 15 
  Since the quality of MR equipment has progressed and technical improvements have 16 
been made in MR sequences, many studies have recently demonstrated the value of 17 
high-resolution MRI for assessment of carotid plaque components, volume and 18 
morphology.
10-13, 23, 31, 32
 That IPH, which plays a potent role in plaque vulnerability, can 19 
be visualized as intense signals on T1-weighted MR images is generally accepted and 20 
intense signals are generated more frequently by symptomatic, than asymptomatic 21 
carotid plaque.
10, 15, 33
 The MR signal of IPH is obviously high during the acute phase 22 
and declines over time.
34
 Prospective studies of carotid atherosclerosis have revealed 23 
that stenosis with IPH detected by MRI confers higher risk for ischemic events than that 24 
10 
 
without IPH in either symptomatic
35
 or asymptomatic patients.
17
 Considering the many 1 
reports describing MRI plaque evaluation of patients with carotid stenosis, regarding 2 
plaques with high-signal on T1-weighted MR images as being unstable and at high risk 3 
for ischemic stroke seems appropriate. 4 
  Few studies have examined the outcomes of medical treatment for symptomatic 5 
low-grade carotid stenosis. The European Surgery Carotid Trial (ECST) reported only a 6 
1.3% rate of ipsilateral ischemic strokes lasting beyond seven days in patients with 7 
symptomatic mild (0-29%) carotid stenosis during three years of follow-up (0.43% per 8 
year) when stroke recurrence assessment was based on merely stenosis rate evaluation.
36 
9 
Among patients with < 50% stenosis in the NASCET study, the 5-year rate of any 10 
ipsilateral stroke was 18.7% in the medically treated group (3.74% per year).
3
 Fritz et al. 11 
reported an 8.6% rate of ischemic events including TIA and stroke during two years of 12 
follow-up (4.3% per year) in 35 medically treated symptomatic patients with low grade 13 
stenosis (< 50%) or ulcerated plaques.
37
 Although the rate of recurrent ischemic events 14 
has some variation among these studies, probably because of differences in the 15 
definition of ischemic events or rate of stenosis, they nevertheless concluded that 16 
patients with symptomatic low-grade stenosis did not benefit from CEA because the 17 
outcome of medical treatment was favorable. 18 
  To the best of our knowledge, only Altaf et al.
20
 prospectively analyzed recurrence 19 
risk based on MRI plaque evaluation in addition to rates of stenosis among patients with 20 
symptomatic carotid low-grade stenosis. They showed that the rates of recurrent 21 
ischemic events in patients with symptomatic mild stenosis (30-49%) treated medically 22 
during a median follow-up period of 28 months were 25% and 10% in plaques with IPH 23 
detected or not by MRI, respectively. They concluded that carotid plaques with intense 24 
11 
 
signals on T1-weighted MR images are at higher risk for ischemic recurrence even 1 
when the rate of stenosis is not significant. 2 
  The present retrospective analysis found ischemic recurrence in 44% of medically 3 
treated patients who had high-signal plaque and expansive remodeling on T1-weighted 4 
carotid MR images, and an annual recurrence rate reached 46.0% per patient-year. A 5 
detailed comparative discussion is limited because reports on outcomes of medical 6 
treatment for symptomatic mild stenosis based on MRI plaque evaluation are scarce. 7 
Nonetheless, we can offer some explanations for the remarkably high rate of ischemic 8 
recurrence in this study. Recurrence in our report included both stroke and TIA. The 9 
recurrence rate excluding TIA in this study was still high at 36.8% per patient-year. 10 
Stroke was diagnosed based on diffusion-weighted images regardless of the severity of 11 
ischemic symptoms. The chances of an oversight in ischemic events seemed low 12 
because patients were regularly followed up at a single institution. More importantly, 13 
the fact that our study patients had not only carotid plaque with IPH detected by MRI 14 
but also expansive remodeling might explain why our patients were at higher risk for 15 
ischemic events than those described by Altaf et al. Expansive plaque remodeling in 16 
patients with coronary artery atherosclerosis has been considered a major factor in 17 
vulnerable plaque.
18, 19
 A study using a murine model of carotid artery lesions found that 18 
the macrophages characteristic of vulnerable plaques assist in expansive remodeling by 19 
promoting matrix degeneration through matrix metalloproteinase secretion.
38
 A recent 20 
study of human carotid atherosclerosis using multidetector CT angiography also found 21 
that the incidence of expansive remodeling is much higher among symptomatic, than 22 
asymptomatic carotid plaques and that the extent of expansive remodeling correlated 23 





  With respect to the safety of CEA for treating symptomatic carotid stenosis, large 1 
clinical trials have shown that the perioperative complication rate does not depend on 2 
the rate of carotid stenosis. Rates of death, disabling stroke, or any other stroke 3 
producing symptoms for more than seven days in the ECST report were 3.7% (70-99%) 4 
and 2.3% (0-29%) for severe and mild stenosis, respectively, with no statistically 5 
significant difference.
36
 In addition, NASCET did not find a significant difference in the 6 
rate of disabling stroke at 30 days between groups with moderate (2.8%) and severe 7 
(3.0%) stenosis.
39
 The fact that diffusion-weighted MR imaging in the present study 8 
confirmed the absence of perioperative ischemic events demonstrated the safety of CEA 9 
for patients with symptomatic low-grade stenosis. None of the patients described herein 10 
has presented with TIA or any stroke, even though they were treated with only single 11 
antiplatelet drugs after CEA for a median postoperative follow-up of 19 months. 12 
Therefore, our results might also indicate the relevance of CEA for patients with 13 
symptomatic low-grade stenosis accompanied by vulnerable plaque confirmed by MRI, 14 
although this assertion is limited by the number of patients studied and the short period 15 
of postoperative follow-up. 16 
Carotid endarterectomy was adopted as a therapeutic option for patients who were 17 
refractory to multidisciplinary medical treatment in this study. However, we could not 18 
find distinctive differences in the patients’ characteristics and MRI findings between the 19 
recurrence and non-recurrence groups, which remains an issue. To discriminate patients 20 
with low-grade carotid stenosis refractory to medical treatment before recurrences or 21 
screen extremely vulnerable plaques with diagnostic imaging remains challenging. In 22 
addition to IPH and expansive arterial remodeling, fibrous cap rupture is also an 23 
important feature of vulnerable plaques. In fact, a prospective study of asymptomatic 24 
13 
 
carotid stenosis with MRI plaque evaluation has demonstrated that ruptured fibrous caps 1 
more significantly influence ischemic events than IPH.
17
 Precise assessment of fibrous 2 
cap status would thus seem key to discriminating extremely vulnerable plaques. Several 3 
studies of MRI plaque characterization have shown that ruptured or thin fibrous caps 4 
can be detected as “dark bands” on TOF images25, 32, 40 and have demonstrated a 5 
moderate to good correlation between MRI findings and CEA specimens for diagnosing 6 
ruptured caps. However, these reports also pointed out the limitation of fibrous cap 7 
estimation by MRI due to poor image quality when the internal carotid artery is 8 
obviously angulated or tortuous or when plaques are densely calcified. In fact, 18-34% 9 
of the patients who underwent carotid MRI were excluded from analysis of the fibrous 10 
cap in these studies. The present study found that the preoperative estimation of fibrous 11 
cap from TOF MR images agreed with histological findings of excised plaques in only 4 12 
of 7 patients. Thus, MRI is not yet satisfactory for fibrous cap assessment in the clinical 13 
setting. Improved spatial- and contrast-to-noise ratios, better spatial resolution using a 14 
higher magnetic field and faster imaging procedures will allow the identification of finer 15 
structures within atherosclerotic arterial walls
41
 and enable more precise diagnosis of 16 
high-risk plaques for recurrent ischemic events. 17 
  The preventive effect against ischemic stroke for low-grade vulnerable stenosis 18 
between CEA and medical treatment should be compared. While anti-thrombotic drugs 19 
have been widely used to prevent strokes,
42
 more aggressive medical treatment with 20 
dual anti-platelet medication with aspirin and clopidogrel is apparently more effective 21 
than aspirin alone.
43
 In addition, statins seem to be appreciably effective against many 22 
disorders caused by systemic atherosclerosis. The ability of aggressive lipid-lowering 23 
therapy with statins to reduce the incidence of ischemic stroke has been verified by 24 
14 
 
several large randomized studies.
44, 45
 In addition, high-resolution MRI studies have 1 
demonstrated that statins suppress, stabilize and reduce carotid atherosclerotic 2 
plaque.
46-48
 Thus, the outcome of medical treatment for carotid stenosis should be 3 
significantly improved by early multifaceted medical intervention for patients with 4 
high-risk atherosclerotic disease. Comparing the long-term results between CEA and 5 
aggressive medical treatment is mandatory to validate the use of CEA for low-grade 6 
high-risk stenosis. 7 
One limitation of the present study is that it was a retrospective analysis of a small 8 
patient cohort over a relatively short follow-up period. Importantly, our patients did not 9 
have symptomatic low-grade carotid stenosis but had plaque with positive remodeling 10 
that was evident on high-signal on T1-weighted images. Therefore, the present findings 11 
are not applicable to symptomatic low-grade stenosis in general. Nevertheless, our 12 
findings promote awareness of the limitations of future stroke risk assessment based 13 
solely on the severity of carotid stenosis. 14 
Conclusion 15 
  Among patients with symptomatic low-grade carotid stenosis, those with plaque 16 
containing IPH demonstrated by MRI undergoing outward remodeling were associated 17 
with a high rate of stroke recurrence regardless of medical treatment. Carotid 18 
endarterectomy prevented further stroke in patients who were refractory to aggressive 19 
medical therapy and was validated for treating a subset of patients with low-grade, but 20 
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Figure legends 1 
 2 
Figure 1. Angiographic and MR images of left carotid artery obtained from Patient 5. 3 
 4 
A. Preoperative digital subtraction angiography (DSA) image acquired after two strokes 5 
that were refractory to medical treatment. Bulb shows slight luminal irregularity but 6 
only 26% stenosis based on North American Symptomatic Carotid Endarterectomy 7 
Trial (NASCET) criteria.  8 
B. Long-axis T1-weighted black-blood MR image of carotid bifurcation shows large 9 
amount of plaque without significant narrowing of internal carotid artery (ICA lumen; 10 
expansive arterial remodeling).  11 
C. T1-weighted black-blood MR image perpendicular to long axis of ICA at bifurcation 12 
also indicates expansive remodeling. *ICA lumen. SCM, sternocleidomastoid muscle. 13 
D. Excised carotid plaque has yellowish luminal surface at carotid bifurcation and 14 
extensively thinned and partially disrupted fibrous cap on luminal surface of the ICA. 15 






























   roSI, relative overall signal intensity on axial T1-weighted images of whole carotid plaque except for lumen at maximal stenosis relative to adjacent      
sternocleidomastoid muscle.;
23
 f/u, follow-up. 
 
 
 Total (n=25) Recurrence (n=11) No recurrence (n=14) P value 
Age (years) 74.2  5.6 73.7  7.2 74.6  4.2 0.716 
     
Gender (male) 23 (92.0%) 10 (90.9%) 13 (92.9%) 0.697 
     
Hypertension 21 (84.0%) 10 (90.9%) 11 (78.6%) 0.396 
Hyperlipidemia 18 (72.0%) 9 (81.8%) 9 (64.3%) 0.305 
Diabetes 8 (32.0%) 4 (36.4%) 4 (28.6%) 0.504 
Ischemic heart disease 10 (40.0%) 4 (36.4%) 6 (42.9%) 0.534 
Atrial fibrillation 3 (12.0%) 2 (18.2%) 1 (7.1%) 0.407 
     
Medical treatment     
Statins 17 (68%) 9 (81.8%) 8 (57.1%) 0.19 
Dual antiplatelet drugs 15 (60%) 9 (81.8%) 6 (42.9%) 0.058 
Warfarin 2 (8%) 2 (18.2%) 0 0.183 
     
roSI of carotid MRI 1.65  030 1.70  0.27 1.61  0.32 0.459 
Number of recurrences  2.7 (1-6) 0  
f/u period (months) 31.3  16.4 34.3  16.6 29.0  16.4  


























No, number; SD, standard deviation; DSA, digital subtraction angiography; roSI, relative overall signal intensity; MRI, magnetic resonance imaging;  
DWI, diffusion weighted image; mRS, modified Rankin scale; f/u, follow-up. 
No. of patients 1 2 3 4 5 6 7  Average SD 
Age (years) /gender (M/F) 80/M 68/M 72/M 74/M 73/M 77/M 73/F  73.9 3.8 
Duration from initial stroke 
to CEA (months) 
 
60 18 46 16 24 49 35 
 
35.4 16.9 
No. of recurrences 6 6 2 1 2 2 4  3.3 2.1 
Rate of stenosis 25 25 47 13.6 26.3 27.8 25.3  27.1 9.9 
Ulceration on DSA + - + - - - -    
roSI on carotid MRI 2.12 1.58 2.08 1.77 1.87 1.88 1.61  1.84 0.21 
Histological findings           
Intraplaque hemorrhage + + + + + + +    
Status of fibrous cap Ruptured Eroded Ruptured Eroded Ruptured Ruptured Ruptured    







- - - - 
 
  
mRS on discharge 1 0 1 1 1 1 1    
Ischemic events after CEA - - - - - - -    
f/u period (months) 47 24 23 17 14 5 4  19.1 14.6 
